Some of the findings echo results from previous research, but co-author Dr. David Fisman believes the study is the first large-scale analysis to include Canadian data.
Pertuzumab and trastuzumab plus paclitaxel strong survival outcomes in HER2+/HR- early breast cancer. Results from the WSG (West German Study Group)-ADAPT Her2+/HR- trial at the 2021 ASCO conference.